Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

Open Access Highly Accessed Research article

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

Ines Vaz-Luis12*, Rebecca A Ottesen3, Melissa E Hughes1, P Kelly Marcom4, Beverly Moy5, Hope S Rugo6, Richard L Theriault7, John Wilson8, Joyce C Niland3, Jane C Weeks1 and Nancy U Lin1

Author Affiliations

1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

2 Clinical and Translational Oncology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal

3 Department of Information Sciences, City of Hope Comprehensive Cancer Center, Duarte, CA, USA

4 Department of Medical Oncology, Duke University Medical Center, Durham, NC, USA

5 Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

6 Department of Medicine, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

7 Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

8 Department of Internal Medicine, Arthur G. James Cancer Hospital, Ohio State University, Columbus, OH, US

For all author emails, please log on.

Breast Cancer Research 2012, 14:R129  doi:10.1186/bcr3324


See related editorial by Norton and Perez, http://breast-cancer-research.com/content/15/1/101

Published: 1 October 2012

Abstract

Introduction

In gene expression experiments, hormone receptor (HR)-positive/human epidermal growth factor-2 (HER2)-positive tumors generally cluster within the luminal B subset; whereas HR-negative/HER2-positive tumors reside in the HER2-enriched subset. We investigated whether the clinical behavior of HER2-positive tumors differs by HR status.

Methods

We evaluated 3,394 patients who presented to National Comprehensive Cancer Network (NCCN) centers with stage I to III HER2-positive breast cancer between 2000 and 2007. Tumors were grouped as HR-positive/HER2-positive (HR+/HER2+) or HR-negative/HER2-positive (HR-/HER2+). Chi-square, logistic regression and Cox hazard proportional regression were used to compare groups.

Results

Median follow-up was four years. Patients with HR-/HER2+ tumors (n = 1,379, 41% of total) were more likely than those with HR+/HER-2+ disease (n = 2,015, 59% of total) to present with high histologic grade and higher stages (P <0.001). Recurrences were recorded for 458 patients. HR-/HER2+ patients were less likely to experience first recurrence in bone (univariate Odds Ratio (OR) = 0.53, 95% Confidence Interval (CI): 0.34 to 0.82, P = 0.005) and more likely to recur in brain (univariate OR = 1.75, 95% CI: 1.05 to 2.93, P = 0.033). A lower risk of recurrence in bone persisted after adjusting for age, stage and adjuvant trastuzumab therapy (OR = 0.53, 95% CI: 0.34 to 0.83, P = 0.005) and when first and subsequent sites of recurrence were both considered (multivariable OR = 0.55, 95% CI: 0.37 to 0.80, P = 0.002).

As compared with patients with HR+/HER2+ disease, those with HR-/HER2+ disease had significantly increased hazard of early, but not late, death (hazard ratio of death zero to two years after diagnosis = 1.92, 95% CI: 1.28 to 2.86, P = 0.002, hazard ratio of death two to five years after diagnosis = 1.55, 95% CI: 1.19 to 2.00, P = 0.001; hazard ratio of death more than five years after diagnosis = 0.81, 95% CI: 0.55 to 1.19, P = 0.285, adjusting for age, race/ethnicity, stage at diagnosis, grade and year of diagnosis).

Conclusions

Presenting features, patterns of recurrence and survival of HER2-positive breast cancer differed by HR status. These differences should be further explored and integrated in the design of clinical trials.